即時搜尋
中華 A80 指數 :
中華香港內地指數 :
中國 120 指數 :
大市總成交 :

Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

2024-05-23 13:10:00

Restylane® VOLYME™ is designed for contouring and volumization of the mid-face region to support patients in achieving a youthful, revitalized look
The complementary Shape Up Holistic Individualized Treatment (HIT™) has also been introduced in China, empowering aesthetics practitioners to deliver dynamic and natural mid-face solutions for their patients
Galderma is committed to delivering its world-leading portfolio of innovative aesthetics solutions to China as well as other countries and regions around the world

ZUG, Switzerland--()--Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.1

Developed using Galderma’s proprietary OBT™* gel technology, Restylane® VOLYME™ is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.2-3 Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.4 In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.1

Developed with a global community of injectors, the Shape Up HIT™ is the latest of Galderma’s HITs™ to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.

原文連結

美國商業資訊

2024-06-14
16:29:00
Celltrion 賽特瑞恩在 EULAR 2024 上展示了 CT-P47(RoActemra® [托珠單抗]的生物相似藥)治療類風濕性關節炎患者的 III 期研究取得的積極成果
10:49:00
Brightcove技術支援服務恐怖、驚悚與真實犯罪影片愛好者的新串流平台FrightPix
10:21:00
80%的企業認為不足或過時的技術阻礙了創新
10:05:00
「2024年東京WORLDCOM獎」於2024年6月5日舉行頒獎典禮
09:56:00
OPEX ® Corporation榮獲SupplyTech Breakthrough頒贈2024年「年度分類系統創新獎」
09:20:00
Corona Cero Inspires Fans to Embrace Golden Moments
2024-06-13
16:25:00
NorthWall Capital為歐洲機會策略融資超過6.4億歐元
16:19:00
Boomi Research 發現克服企業老舊系統挑戰,可組合性至關重要
11:26:00
RegenLab France榮獲久負盛名的歐盟及歐洲投資銀行創新冠軍獎
11:20:00
盈透證券新增芝加哥選擇權交易所歐洲衍生性商品(CEDX)交易
11:17:00
GSK與Ochre Bio達成一項多年期資料授權協議,協助Ochre Bio進一步探究肝病成因
11:10:00
Transphorm 推出適用於電動交通與能源/工業市場的新型雙向 SuperGaN 電源參考設計
11:07:00
PUMA透過歐洲杯和美洲杯衍生活動繼續推進其最大的市場行銷活動
10:10:00
Juniper Networks Wins Four Top Awards at Interop Tokyo 2024
10:02:00
AWS將在臺灣啟動基礎設施區域
09:56:00
Shin-Etsu Chemical:開發用於後端製程的半導體封裝基板製造設備並尋求新的製造方法
09:32:00
Global Corona Brand Named Most Valuable Beer Brand in Kantar BrandZ Rankings
2024-06-12
16:19:00
旅發局與巴塞爾藝術展簽訂三年全球策略合作協議
16:04:00
DNP黑崎工廠用於OLED製造的金屬遮罩生產線開始運作
15:59:00
Bridgestone推出的印地自動駕駛挑戰賽將於2024年7月重返古德伍德速度節
回頁頂